From Physician to Pharma: Gynecologic Oncologist Enters Clinical Trials Space

Making a big change mid-career is no small feat, which is something Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, knows from experience. In this exclusive interview with Pharmaceutical Executive®, Garner reveals what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically in clinical trials.

Enjoy this video and want to watch more? Check out the full Pharm Exec Podcast episode.

About the speaker

Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, is responsible for US clinical development, medical affairs, pharmacovigilance, project planning, and regulatory affairs at Ferring Pharmaceuticals US. Garner has nearly 30 years of experience in the medical industry. Prior to joining Ferring in 2022, she held chief medical officer roles for ObsEva, a biotechnology company focused on women’s health, and Agile Therapeutics, a women’s healthcare company. Earlier, she held leadership roles in medical affairs at Myriad Genetics Laboratories and clinical development at Abbott Laboratories and Merck Research Laboratories. Garner also holds a medical degree from Harvard Medical School and has practiced in obstetrics, gynecology, gynecologic oncology, and internal medicine at Brigham and Women’s Hospital and Massachusetts General Hospital. In addition, she holds a master’s degree in public health from Harvard’s T.H. Chan School of Public Health and a bachelor’s degree from Mount Holyoke College in Massachusetts.

About the Pharm Exec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.